<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is a <z:hpo ids='HP_0011010'>chronic</z:hpo> illness that is increasing in epidemic proportions worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Major factors contributing to the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> include <z:hpo ids='HP_0001513'>obesity</z:hpo> and poor lifestyle habits (e.g., excess dietary intake and limited physical activity) </plain></SENT>
<SENT sid="2" pm="."><plain>Despite the proven efficacy of lifestyle interventions and the use of multiple pharmacological agents, the economic and public health burden of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> remains substantial </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002870'>Obstructive sleep apnea</z:hpo> (OSA) is a treatable <z:e sem="disease" ids="C0851578" disease_type="Disease or Syndrome" abbrv="">sleep disorder</z:e> that is pervasive among overweight and <z:mp ids='MP_0001261'>obese</z:mp> adults, who represent about two thirds of the U.S. population today </plain></SENT>
<SENT sid="4" pm="."><plain>An ever-growing number of studies have shown that OSA is associated with <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, independent of <z:hpo ids='HP_0001513'>obesity</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Evidence from animal and human models that mimic OSA provides potential mechanisms for how OSA may alter <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="6" pm="."><plain>Up to 83% of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> suffer from unrecognized OSA and increasing severity of OSA is associated with worsening <z:chebi fb="105" ids="17234">glucose</z:chebi> control </plain></SENT>
<SENT sid="7" pm="."><plain>However, it is still unclear whether OSA may lead to the development of <z:mp ids='MP_0002055'>diabetes</z:mp> over time </plain></SENT>
<SENT sid="8" pm="."><plain>More data from large-scale longitudinal studies with rigorous assessments of <z:mp ids='MP_0002055'>diabetes</z:mp> and OSA are needed </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, there is still controversy whether continuous positive airway pressure (CPAP) treatment of OSA improves <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism </plain></SENT>
<SENT sid="10" pm="."><plain>Large-scale randomized-controlled trials of CPAP treatment of OSA with well-validated assessments of insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance are needed </plain></SENT>
<SENT sid="11" pm="."><plain>These studies may reveal that OSA represents a novel, modifiable risk factor for the development of <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetes</z:e> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>